Clearmind Medicine Advances CMND-100 Clinical Trials for Alcohol Use Disorder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Globenewswire
- Clinical Trial Progress: Clearmind successfully initiated its FDA-approved Phase I/IIa trial for CMND-100 at prestigious institutions like Yale and Johns Hopkins, achieving first-in-human dosing and demonstrating a favorable safety profile, marking a significant advancement in treating Alcohol Use Disorder.
- Safety Endorsement: The Data and Safety Monitoring Board unanimously approved the continuation of the clinical trial, reinforcing CMND-100's safety profile and laying a solid foundation for future data readouts, which boosts investor confidence.
- Global Footprint Expansion: Clearmind strengthened its intellectual property portfolio with multiple international patent filings targeting various indications, including weight loss and depression, showcasing the company's strategic positioning across multiple therapeutic areas.
- Future Outlook: Looking ahead to 2026, Clearmind aims to advance its pipeline, generate additional clinical data, and explore strategic opportunities to maximize shareholder value and patient impact, demonstrating its long-term commitment to the market.
CMND
$2.24+Infinity%1D
Analyst Views on CMND
About CMND
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
